Abstracts tagged "giant cell arteritis"

Abstract Number: 0488 • ACR Convergence 2022
Discrepancies in Temporal Artery Biopsy Positivity Rate Among White and Black Patients Suspected of Having Giant Cell Arteritis: Experience from a Tertiary Academic Medical Center
Raj Vachhani¹, Peng Li², Mehdi Tavakoli², Lanning Kline² and Angelo Gaffo², ¹University of Alabama at Birmingham, Homewood, AL, ²University of Alabama at Birmingham, Birmingham, AL
Background/Purpose: A prior study evaluated incidence rates of biopsy proven giant cell arteritis (GCA) among black and white patients, concluding that GCA occurs at a…
Abstract Number: 1545 • ACR Convergence 2022
Increased Neutrophil Activation in Patients with Polymyalgia Rheumatica
Despina Michailidou¹, Linda Johansson², Runa Kuley¹, TING WANG¹, Payton Hermanson¹, Solbritt Rantapää-Dahlqvist² and Christian Lood¹, ¹Division of Rheumatology, University of Washington, Seattle, WA, ²Department of Public Health and Clinical Medicine, Rheumatology, Umeå University, Umeå, Sweden
Background/Purpose: Neutrophils are important in host defense. However, neutrophil activation has also been involved in the immunopathogenesis of several autoimmune diseases due to their many…
Abstract Number: 0473 • ACR Convergence 2022
Comprehensive Assessment of Cranial and Orbital Vasculature on MRI in Patients with Giant Cell Arteritis
Rennie Rhee, Shubhasree Banerjee, Vatsal Bhatt, Madhura Tamhankar, Naomi Amudala, Sherry Chou, Morgan Burke, Laurie Loevner, Peter Merkel and Jae Song, University of Pennsylvania, Philadelphia, PA
Background/Purpose: Vessel wall MRI depicts changes consistent with arterial wall inflammation. Unlike temporal artery biopsy, MRI visualizes several full-length cranial arteries in a single scan…
Abstract Number: 0489 • ACR Convergence 2022
Giant Cell Arteritis Phenotypes and Diagnosis of Aortitis Among 1852 Patients Before and After 2016 Across 10 French Referral Centers
Laurent Sailler¹, Kim Ly², Hubert De Boysson³, Brigitte Granel⁴, Maxima Samson⁵, Christian Agard⁶, Laurence Bouillet⁷, Magnan Julie⁸, Marc Lambert⁹, Arsene Mekinian¹⁰, Lea Tarallo¹, Eric Liozon², Gregory Pugnet¹¹, Jean Luc Davignon¹, Achille Aouba¹², Aurélie Daumas⁴, Quentin Gomes de Pinho⁴, bernard bonnotte¹³, simon parreau², Samuel Deshayes¹² and GEFA Collaborative group¹⁴, ¹CHU Toulouse, Toulouse, France, ²CHU Limoges, Limoges, France, ³Department of Internal Medicine, UR4650 PSIR, Normandie Univ, UNICAEN, CHU de Caen Normandie, Caen, France, ⁴AP-HM, Marseille, France, ⁵Dijon University Hospital, Dijon, France, ⁶Internal medicine, Nantes University Hospital, Nantes, France, ⁷Grenoble University Hospital, Grenoble, France, ⁸CHU Tours, Tours, France, ⁹CHU Lille, Lille, France, ¹⁰AP-HP, Hopital Saint Antoine, Paris, France, ¹¹CHU Toulouse Purpan Service de Medecine Interne, Toulouse, France, ¹²CHU Caen, Caen, France, ¹³Centre Hospitalo-Universitaire de Dijon, Dijon, France, ¹⁴Saint Joseph Hospital, Marseille, France
Background/Purpose: In 2016, French Internal medicine physicians collaborating in the Groupe d'Etude Français de l'Arterite à cellules géantes (GEFA) created a common database to build…
Abstract Number: 1573 • ACR Convergence 2022
Von – Willebrand Factor, a Possible Marker for Disease Activity in Vasculitis
Jomana mazareeb¹, shiri keret¹, Abid Awisat¹, Itzhak Rosner², Michel Rozenbaum³, Lisa Kaly¹, Gleb Slobodin¹ and Doron Rimar¹, ¹Bnai Zion Medical Center, Haifa, Israel, ²Bnai Zion Medical Center/Technion, Haifa, Israel, ³Bnei Zion Medical Center, Hertzeliya, Israel
Background/Purpose: Vasculitis is an inflammation of blood vessels. While in many cases markers of inflammation as c- reactive protein (CRP) or erythrocytes sedimentation rate (ESR)…
Abstract Number: 0474 • ACR Convergence 2022
Utility of Optimization of Tocilizumab Therapy in Giant Cell Arteritis: A Multicenter Study of 471 Patients
Fabricio Benavides Villanueva¹, Cristina Corrales¹, Javier Loricera², Monica Calderón-Goercke¹, Clara Moriano³, Santos Castañeda⁴, FRANCISCO JAVIER NARVAEZ⁵, Vicente Aldasoro⁶, Olga Maiz⁷, Rafael Melero⁸, Juan Ignacio Villa⁹, Paloma Vela-Casampere¹⁰, Susana Romero Yuste¹¹, José Luis Callejas¹², Eugenio De Miguel¹³, Eva Galíndez-Agirregoikoa¹⁴, Francisca Sivera¹⁵, Jesús Carlos Fernández-López¹⁶, Carles Galisteo¹⁷, Ivan Ferraz Amaro¹⁸, JULIO SANCHEZ MARTIN¹, Lara Sánchez-Bilbao¹, Jose Luis Hernández¹, Miguel Angel Gonzalez Gay¹⁹ and Ricardo Blanco², ¹Hospital Universitario Marqués de Valdecilla, Santander, Spain, ²Hospital Universitario Marqués de Valdecilla, IDIVAL, Santander, Spain, ³Complejo Asistencial Universitario de León, León, Spain, ⁴Division of Rheumatology, Hospital Universitario de La Princesa, IIS-Princesa, Madrid, Spain, ⁵Hospital de Bellvitge, Barcelona, Spain, ⁶Hospital Universitario de Navarra, Pamplona, Spain, ⁷Hospital Universitario de Donostia, San Sebastián, Spain, ⁸Complexo Hospitalario Universitario de Vigo, Vigo, Spain, ⁹Hospital Sierrallana, Torrelavega, Spain, ¹⁰Hospital General Universitario Alicante, Alicante, Spain, ¹¹Complexo Hospitalario Universitario, Pontevedra, Spain, ¹²Hospital San Cecilio, Granada, Andalucia, Spain, ¹³Hospital Universitario La Paz, Madrid, Spain, ¹⁴Basurto University Hospital, Bilbao, Spain, ¹⁵Hospital Universitario de Elda, San Vicente del Raspeig, Spain, ¹⁶Complejo H. Universitario de A Coruña, A Coruña, Spain, ¹⁷Hospital Parc Tauli,, Sabadel, Spain, ¹⁸Division of Rheumatology. Hospital Universitario de Canarias. Spain., Santa Cruz de Tenerife, Spain, ¹⁹Hospital Universitario Marques de Valdecilla, Lugo, Spain
Background/Purpose: Tocilizumab (TCZ) has shown to be useful in the treatment of large-vessel vasculitis, including giant cell arteritis (GCA). There is general agreement on the…
Abstract Number: 0490 • ACR Convergence 2022
Analysis of Emergency Department Visits by Patients with Giant Cell Arteritis: A National Population-based Study
Ehizogie Edigin¹, Amy Trang², Chinenye Osuorji³, Solomon Anighoro⁴, Precious Eseaton⁵, Christopher Hino¹, Osahon Idolor⁶, Nneka Chukwu⁷, Anum Akhlaq⁸ and Mehrnaz Hojjati¹, ¹Loma Linda University Health, Loma Linda, CA, ²Rush University Medical Center, Chicago, IL, ³Montefiore Medical Center/ Albert Einstein College of Medicine, Bronx, NY, ⁴St. Helens and Knowsley Teaching hospitals NHS Trust, Prescot, England, United Kingdom, ⁵University of South Wales, Cardiff, Wales, United Kingdom, ⁶Piedmont Athens Regional, Atlanta, GA, ⁷Nuvance Health, Poughkeepsie, ⁸University of Mississippi Medical Center, Jackson, MS
Background/Purpose: Giant Cell Arteritis (GCA) is the most common vasculitis in patients older than 50 years of age. GCA has significant economic burden and increases…
Abstract Number: 1615 • ACR Convergence 2022
Myocardial Infarction in Patients with Systemic Vasculitis and Population Controls: Characteristics and Overall Mortality
Pavlos Stamatis¹, Moman Mohammad², David Erlinge², Carl Turesson³, David Jayne⁴ and Aladdin Mohammad⁵, ¹Department of Clinical Sciences Lund, Rheumatology, Lund University, Sweden, Larissa, Larisa, Greece, ²Department of Clinical Sciences Lund, Cardiology, Lund University, Lund, Sweden, ³Rheumatology, Department of Clinical Sciences, Malmö, Lund University, Malmö, Sweden, ⁴University of Cambridge, Cambridge, United Kingdom, ⁵Rheumatology, Department of Clinical Sciences, Lund University, Lund, Sweden
Background/Purpose: The deleterious effect of inflammation combined with glucocorticoid treatment may increase the risk for atherosclerotic events. The aims of this study were to investigate…
Abstract Number: 0458 • ACR Convergence 2022
Predictive Models for Thromboembolic Events in Giant Cell Arteritis: A US Veterans Health Administration Population-Based Study
Despina Michailidou¹, Tianyu Zhang², Andreas Diamantopoulos³, Pavlos Stamatis⁴ and Bernard Ng⁵, ¹Division of Rheumatology, University of Washington, Seattle, WA, ²Department of Biostatistics, University of Washington, Seattle, WA, ³Akershus University Hospital, Lørenskog, Norway, ⁴Department of Clinical Sciences Lund, Rheumatology, Lund University, Sweden, Larissa, Larisa, Greece, ⁵Rheumatology Section, VA Puget Sound Healthcare System, Seattle, WA
Background/Purpose: Giant cell arteritis (GCA) is an independent risk factor for thromboembolic events. The purpose of our study was to identify prognostic factors for thromboembolic…
Abstract Number: 0475 • ACR Convergence 2022
Whole-country and Regional Incidences of Giant Cell Arteritis in French Continental and Overseas Territories: A Nationwide Database Analysis
Hubert De Boysson¹, Lydia GUITTET², Damiano CERASUOLO², Rémy MORELLO², Samuel DESHAYES² and Achille Aouba¹, ¹Department of Internal Medicine, UR4650 PSIR, Normandie Univ, UNICAEN, CHU de Caen Normandie, Caen, France, ²Caen University Hospital, Caen, France
Background/Purpose: The incidence rate of giant cell arteritis (GCA) is poorly studied in France. Therefore, we conducted a national hospital database study to assess the…
Abstract Number: 0491 • ACR Convergence 2022
Markers of Neutrophil Activation in Patients with ANCA-associated Vasculitis and Large-vessel Vasculitis
Despina Michailidou¹, Bhargavi Duvvuri¹, Runa Kuley¹, David Cuthbertson², Peter Grayson³, Nader Khalidi⁴, Curry Koening⁵, Carol Langford⁶, Carol McAlear⁷, Larry Moreland⁸, Christian Pagnoux⁹, Philip Seo¹⁰, Ulrich Specks¹¹, Antoine Sreih⁷, Kenneth J. Warrington¹¹, Tomas Mustelin¹, Paul Monach¹², Peter Merkel¹³ and Christian Lood¹, ¹Division of Rheumatology, University of Washington, Seattle, WA, ²University of South Florida, Tampa, FL, ³National Institutes of Arthritis and Musculoskeletal and Skin Diseases (NIAMS), National Institutes of Health (NIH), Bethesda, MD, ⁴Division of Rheumatology, Mc Master University, Ontario, Canada, Ontario, Canada, ⁵Division of Rheumatology, University of Utah, Salt Lake City, UT, USA, Salt Lake City, UT, ⁶Cleveland Clinic, Cleveland, OH, ⁷Division of Rheumatology, University of Pennsylvania, Philadelphia, PA, USA, Philadelphia, PA, ⁸University of Colorado, Denver, CO, ⁹Division of Rheumatology, Mount Sinai Hospital, Toronto, ON, Canada, ¹⁰Johns Hopkins University, Baltimore, MD, ¹¹Mayo Clinic, Rochester, MN, ¹²VA Boston Healthcare System, Boston, MA, ¹³University of Pennsylvania, Philadelphia, PA
Background/Purpose: Neutrophils contribute to the pathogenesis of many autoimmune diseases. The purpose of the study was to assess two markers of neutrophil activation, calprotectin and…
Abstract Number: 1617 • ACR Convergence 2022
Direct Comparison of Ultrasound, [18F]Fluorodeoxyglucose-Positron Emission Tomography/Computed Tomography and Magnetic Resonance Imaging: Early Diagnostics in Patients Suspected of Giant Cell Arteritis
Marieke van Nieuwland¹, Marloes Vermeer¹, Edgar Colin², Nils Wagenaar¹, Onno Vijlbrief¹, Jordy van Zandwijk³, Riemer Slart⁴, Hendrik Koffijberg³, Erik Groot Jebbink³, Elisabeth Brouwer⁴, Dennis Boumans¹ and Celina Alves¹, ¹Hospital Group Twente, Almelo, Netherlands, ²Hospital Group Twente, Deventer, Netherlands, ³University of Twente, Enschede, Netherlands, ⁴University Medical Center Groningen, Groningen, Netherlands
Background/Purpose: Giant cell arteritis (GCA) requires rapid diagnostic work up and start of treatment to prevent severe complications. The temporal artery biopsy as a gold…
Abstract Number: L19 • ACR Convergence 2021
Secukinumab in Giant Cell Arteritis: A Randomized, Parallel-group, Double-blind, Placebo-controlled, Multicenter Phase 2 Trial
Nils Venhoff¹, Wolfgang Schmidt², Raoul Bergner³, Jürgen Rech⁴, Leonore Unger⁵, Hans-Peter Tony⁶, Meryl Mendelson⁷, Christian Sieder⁸, Meron Maricos⁸ and Jens Thiel⁹, ¹Department of Rheumatology and Clinical Immunology, Vasculitis Center Freiburg, Medical Center - University of Freiburg, University of Freiburg, Freiburg, Germany, ²Immanuel Krankenhaus Berlin, Medical Center for Rheumatology Berlin-Buch, Lindenberger Weg 19, 13125 Berlin, Germany, Berlin, Germany, ³Medizinische Klinik A, Klinikum der Stadt Ludwigshafen, Ludwigshafen, Germany, ⁴Department of Internal Medicine 3 - Rheumatology and Immunology, Friedrich-Alexander University (FAU) Erlangen-Nürnberg and Universitätsklinikum Erlangen, 91054,, Erlangen, Germany, ⁵Medical Department 1, Städtisches Klinikum Dresden, Dresden, Germany, ⁶Department of Medicine 2, Rheumatology and Clinical Immunology Oberduerrbachertstr. 697080, Wuerzburg, Germany, ⁷Novartis Pharmaceuticals Corporation, East Hanover, NJ, ⁸Novartis Pharma GmbH, Nuremberg, Germany, ⁹Department of Rheumatology and Clinical Immunology, Vasculitis Center Freiburg, Medical Center - University of Freiburg, University of Freiburg, Freiburg, Germany; Division of Rheumatology and Immunology, Department of Internal Medicine, Medical University of Graz, Graz, Austria
Background/Purpose: Little is known about glucocorticoid-sparing agents in giant cell arteritis (GCA) except for IL-6 inhibition. Secukinumab (SEC) has shown significant improvements in the signs…
Abstract Number: 1394 • ACR Convergence 2021
Vascular Ultrasound for Giant Cell Arteritis: An Effective Diagnostic Modality for a Fast Track Clinic in the United States
Charlie Oshinsky¹, Alison Bays¹, Ingeborg Sacksen², Elizabeth Jernberg³, Eugene zierler¹, Andreas Diamantopoulos⁴ and Scott Pollock¹, ¹University of Washington, Seattle, WA, ²University of Washington, Bellingham, WA, ³Virginia Mason Medical Center, Seattle, WA, ⁴Akerhus University Hospital, Brum, Norway
Background/Purpose: Giant cell arteritis (GCA) is the most common form of large vessel vasculitis. Prompt diagnosis and treatment of GCA is vital to prevent vision…
Abstract Number: 1411 • ACR Convergence 2021
Decreased Use of Ultrasound Fast-track Pathways of Giant Cell Arteritis Due to COVID-19 Pandemic: A Potential Risk for Permanent Visual Loss
Fernando Montero¹, Juan Molina², ISABEL CASTREJON³, Julia Martínez Barrio¹, Juan Carlos Nieto¹ and Jose Maria Alvaro-Gracia¹, ¹Hospital General Universitario Gregorio Marañón, Madrid, Spain, ²Hospital General Universitario Gregorio Maran, Madrid, Spain, ³Pfizer Spain, Chicago
Background/Purpose: The implementation of ultrasound (US) fast-track pathways (FTP), aiming at an early diagnosis of giant cell arteritis (GCA), has led to a decrease in…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].